Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Triazolam · 1 trial · 1 indication
Driving performance assessment for the participants were measured by simulated driving test using Cognitive Research Corporation Driving Simulator (CRCDS-MiniSim). The assessment was performed after 45 minutes of awakening from approximately 6.5 hours of sleep on testing day (after 7.25 hours of study drug administration). SDLP was used to assess driver's ability to track their lane and was the standard deviation of lane positions through the entire drive.
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | - |
| Arm B | EXPERIMENTAL | - |
| Arm C | ACTIVE_COMPARATOR | - |
| Arm D | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Gabapentin | DRUG | 250 mg, oral, prior to bedtime on the night before performance testing |
| Diphenhydramine citrate | DRUG | 76 mg, oral, prior to bedtime on the night before performance testing |
| Triazolam | DRUG | 0.5 mg, oral, prior to bedtime on the night before performance testing |
| Placebo | DRUG | Oral, prior to bedtime on the night before performance testing |
Inclusion Criteria: * Healthy males and females of non-childbearing potential, 25-55 years of age * Valid driver's license Exclusion Criteria: * Psychiatric disorder * Recent history of clinically significant neurological disorder, such as seizures, stroke, multiple sclerosis, or head trauma * Re...
Triazolam is a small molecule being studied in healthy volunteers. It is being investigated for its effects on next-day residual performance, specifically in the context of simulated driving. The drug is currently in Phase 3 clinical development.
Triazolam is being developed by Pfizer, Inc., a company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 3 clinical development.
Triazolam is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 3 clinical trial has been completed.
Triazolam has been studied in one completed Phase 3 clinical trial, identified as NCT01888497. This trial examined the next-day residual effects of Triazolam on simulated driving performance in normal volunteers.
Triazolam is not the same as gabapentin or diphenhydramine. In a clinical trial, these three drugs were studied together to compare their next-day residual effects on simulated driving performance in healthy volunteers.